San Francisco cell therapy player lays off 94 staffers as it awaits data on lead candidate

19 Jul 2022
endpts.com
Cell Therapy
PACT Pharma, a well-connected cell therapy developer out of South San Francisco, is laying off 94 employees, according to a WARN notice filed in California. Among those heading out are president and COO Tim Moore (who had jumped from Kite three years ago), 14 scientists, 12 director-level positions, seven engineers, a half-dozen vice presidents and two senior directors, the San Francisco Business Times reported . The company will have 40 remaining employees to carry on the work on T cell therapies for cancer, according to the paper. Co-founded by such prominent names as David Baltimore, Jim Heath, Antoni Ribas, Terry Rosen and Juan Jaen, PACT got its name from the products it aims to create: Personalized Adoptive Cell Therapy. The goal, simply put, is to identify patient-specific neoantigen targets and the specific group of T cells driving an immune response — then unleash a whole “tsunami” of T cells engineered to attack the cancer. Specifically, PACT employs a non-viral gene editing process, one that it is coupling with other “complex modifications.” The biotech is conducting a Phase I study of NeoTCR-P1, its lead candidate, against a basket of solid tumors, with or without a PD-1 inhibitorPD-1 inhibitor. While original trial plans called for the enrollment of 148 patients, PACT stopped recruiting new patients in February, according to a listing on clinicaltrials.gov, although the trial is still active. Over the years PACT has raised $266 million across three rounds, with the latest $75 million closing in early 2020. PACT did not respond to a request for comment by press time. FierceBiotech first reported on the WARN notice.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.